News | Mammography | January 06, 2021

World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionize breast screening by allowing it to be tailored to women at minimal extra cost

World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionise breast screening by allowing it to be tailored to women at minimal extra cost

Getty Images


January 6, 2021 — World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionise breast screening by allowing it to be tailored to women at minimal extra cost.

Published in the International Journal of Cancer, the University of Melbourne-led study found two new mammogram-based measures of risk. When these measures are combined, they are more effective in stratifying women in terms of their risk of breast cancer than breast density and all the known genetic risk factors.

Researchers say if successfully adopted, their new measures could substantially improve screening, make it more effective in reducing mortality and less stressful for women, and therefore encourage more to be screened. They could also help address the problem of dense breasts.

Since the late 1970s, scientists have known that women with denser breasts, which shows up on a mammogram as having more white or bright regions, are more likely to be diagnosed with breast cancer and to have it missed at screening.

Collaborating with Cancer Council Victoria and BreastScreen Victoria, University of Melbourne researchers were the first to study other ways of investigating breast cancer risk using mammograms.

Using computer programs to analyze mammogram images of large numbers of women with and without breast cancer, they found two new measures for extracting risk information. Cirrocumulus is based on the image's brightest areas and Cirrus on its texture.

First, they used a semi-automated computer method to measure density at the usual, and successively higher levels of brightness to create Cirrocumulus. They then used artificial intelligence (AI) and high-speed computing to learn about new aspects of the texture (not brightness) of a mammogram that predict breast cancer risk and created Cirrus.

When their new Cirrocumulus and Cirrus measures were combined, they substantially improved risk prediction beyond that of all other known risk factors.

Lead researcher and University of Melbourne Professor John Hopper said that in terms of understanding how much women differ in their risks of breast cancer, these developments could be the most significant since the breast cancer genes BRCA1 and BRCA2 were discovered 25 years ago.

"These measures could revolutionise mammographic screening at little extra cost, as they simply use computer programs," Professor Hopper said.

"The new measures could also be combined with other risk factors collected at screening, such as family history and lifestyle factors, to provide an even stronger and holistic picture of a woman's risk.

"Tailored screening - not 'one size fits all' - could then be based on accurately identifying women at high, as well as low, risk so that their screening can be personalized.

"Given mammography is now digital, and our measures are now computerised, women could be assessed for their risk at the time of screening - automatically - and given recommendations for their future screening based on their personal risk, not just their age."

Professor Hopper said this information could be used to ease pressure on BreastScreen, which had to close for a period during the COVID-19 pandemic and is looking for ways to best handle the backlog while continuing to provide a valuable service with limited resources.

He said the current breakthrough could not have occurred without the extraordinary support his mammogram research had received from the National Breast Cancer Foundation, starting with its first funding round more than 20 years ago.

"Only around 55 per cent of Australian women aged 50-74 currently present for screening aimed at detecting breast cancers early," he said.

"Knowing that screening could also give an accurate risk prediction could encourage more women to take up the offer of free screening. Women with high risk based on their mammogram would also benefit greatly from also knowing their genetic risk."

Adjunct Associate Professor Helen Frazer, Clinical Director of St Vincent's BreastScreen Melbourne, said that improvements in assessing a woman's risk of breast cancer would be transformative for screening programs.

"Using AI developments to assess risk and personalise screening could deliver significant gains in the fight against breast cancer," Adjunct Associate Professor Frazer said.

For more information: www.unimelb.edu.au


Related Content

News | Artificial Intelligence

March 1, 2024 — Royal Philips, a global leader in health technology, and magnetic resonance imaging (MRI) software ...

Time March 01, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Cardiac Imaging

February 28, 2024 — Royal Philips, a global leader in health technology, announced major enhancements to its Image ...

Time February 28, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

February 28, 2024 — Royal Philips, a global leader in health technology, today announced a significant milestone as it ...

Time February 28, 2024
arrow
News | Artificial Intelligence

February 28, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered solutions that enable medical providers ...

Time February 28, 2024
arrow
News | Women's Health

February 27, 2024 — Hologic, Inc. continues to deliver on its commitment to advancing women’s health by unveiling new ...

Time February 27, 2024
arrow
News | Artificial Intelligence

February 27, 2024 — As artificial intelligence (AI) is increasingly used in radiology, researchers caution that it’s ...

Time February 27, 2024
arrow
News | X-Ray

February 26, 2024 — AIxSCAN, Inc. began clinical trials in late 2023. The AIxSCAN, Inc. team is very pleased with the ...

Time February 26, 2024
arrow
News | Breast Imaging

February 23, 2024 — ScreenPoint Medical is showcasing its industry leading Transpara Breast AI at the 2024 European ...

Time February 23, 2024
arrow
News | PACS

February 22, 2024 — aycan, a recognized leader in medical imaging, announced that Enspectra Health used aycan’s PACS ...

Time February 22, 2024
arrow
Subscribe Now